Vanguard Portfolio Management LLC has disclosed a substantial stake in Krystal Biotech, Inc. The recent filing indicates that Vanguard owns 1,312,431 shares of the company, which represents approximately 4.43% of Krystal Biotech's total shares. This significant investment underscores Vanguard's role as a major player in the investment management landscape.

Krystal Biotech, based in Pittsburgh, Pennsylvania, operates in the biological products sector, specifically focusing on innovative therapies. The company's address is 2100 Wharton Street, Suite 701, Pittsburgh, PA 15203. Vanguard's investment comes at a time when the biotechnology industry is experiencing rapid growth and increasing investor interest.

The filing, which is an amendment to a previous Schedule 13G, was made on October 30, 2026, and reflects the securities beneficially owned by Vanguard Portfolio Management. It notes that Vanguard has sole voting power over 25,577 shares and sole dispositive power over the entire 1,312,431 shares reported. This filing highlights Vanguard's strategic position within the biotechnology sector.

This update may impact various stakeholders, including Krystal Biotech, investors, and competitors within the biotechnology industry. Vanguard's ownership could influence shareholder decisions and market perceptions regarding Krystal Biotech's future prospects.

Details regarding future actions or further filings were not specified in the recent disclosure. The filing does not indicate what happens next for Vanguard or Krystal Biotech following this significant update.